GNI Group, headquartered in Japan, is a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative medicines. The company focuses on treating inflammatory diseases and fibrosis through the advancement of novel therapeutic agents.
Date confirmed from the Tokyo Stock Exchange (JPX) announcement schedule.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
GNI Group is scheduled to report its next quarterly earnings on 11/13/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
GNI Group last reported quarterly earnings on 8/14/2026 (Q2 2026). Earnings per share (EPS) came in at 2.54 JPY.
Across its last 3 earnings reports, GNI Group stock moved by ±2.3% on average the following day. The largest reaction was -3.5% on 02/13/2026; 1 of 3 reactions were positive.
GNI Group has beaten analyst EPS estimates in 1 of its last 3 evaluated quarters (beat rate: 33.3%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 3 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.